Yokoyama Teruhiko, Nozaki Kunihiro, Fujita Osamu, Nose Hiroyuki, Inoue Miyabi, Kumon Hiromi
Department of Urology, Okayama University Graduate School of Medicine and Dentistry, Shikata, Okayama, Japan.
J Urol. 2004 Aug;172(2):596-600. doi: 10.1097/01.ju.0000132769.71014.b5.
Resiniferatoxin (RTX) is a specific C fiber neurotoxin which produces desensitization. In this study we performed intravesical RTX therapy in patients with idiopathic detrusor overactivity. In addition we measured the current perception threshold of C and A delta fibers before and after treatment to evaluate clinical significance.
The protocol involved an RTX solution (100 ml of 50 nM) instilled in the bladder for 30 minutes. Four men and 6 women 59 to 75 years old were treated. Effects on bladder function were evaluated before and 30 days after treatment by cystometry and Neurometer (Neurotron, Inc., Baltimore, Maryland). Subjective and objective measures included bladder diaries and quality of life before treatment, and 7, 30 and 90 days subsequently.
Of the 10 patients 5 noted improvement and 2 of them became dry. The other 5 patients were considered to have stationary symptoms. Mean maximal cystometric capacity +/- SD increased from 229 +/- 108 ml at baseline to 271 +/- 99.5 ml at 30 days (p = 0.04). The mean number of daily episodes of urinary incontinence decreased from 3.5 +/- 2.2 to 2.0 +/- 1.6 (p = 0.008) at 7 days, to 1.9 +/- 1.6 (p = 0.018) at 30 days and to 2.5 +/- 1.7 (p = 0.018) at 90 days. Mean current perception threshold values of C and A delta fibers did not change significantly, from 46.9 +/- 35.2 to 56.4 +/- 32.1 (p = 0.161) and from 66.9 +/- 31.7 to 66.4 +/- 25.2 (p = 0.952), respectively. However, values of C fibers increased in all patients who showed improvement from 46.2 +/- 33.2 to 64.0 +/- 36.8 (p = 0.043).
Intravesical RTX improved bladder capacity and leak episodes in patients with idiopathic detrusor overactivity. Intravesical RTX is a promising treatment for this condition.
树脂毒素(RTX)是一种可产生脱敏作用的特异性C纤维神经毒素。在本研究中,我们对特发性逼尿肌过度活动患者进行了膀胱内RTX治疗。此外,我们测量了治疗前后C纤维和Aδ纤维的电流感觉阈值,以评估其临床意义。
方案包括将RTX溶液(100 ml,50 nM)注入膀胱30分钟。治疗了4名男性和6名女性,年龄在59至75岁之间。在治疗前和治疗后30天,通过膀胱测压法和神经测定仪(Neurotron公司,马里兰州巴尔的摩)评估对膀胱功能的影响。主观和客观测量指标包括治疗前、治疗后7天、30天和90天的膀胱日记和生活质量。
10名患者中,5名症状改善,其中2名实现了尿失禁症状消失。另外5名患者症状无变化。平均最大膀胱测压容量±标准差从基线时的229±108 ml增加到30天时的271±99.5 ml(p = 0.04)。每日尿失禁发作的平均次数在7天时从3.5±2.2降至2.0±1.6(p = 0.008),30天时降至1.9±1.6(p = 0.018),90天时降至2.5±1.7(p = 0.018)。C纤维和Aδ纤维的平均电流感觉阈值无显著变化,分别从46.9±35.2变为56.4±32.1(p = 0.161),从66.9±31.7变为66.4±25.2(p = 0.952)。然而,所有症状改善患者的C纤维值均升高,从46.2±33.2升至64.0±36.8(p = 0.043)。
膀胱内RTX可改善特发性逼尿肌过度活动患者的膀胱容量和漏尿发作情况。膀胱内RTX是治疗这种疾病的一种有前景的疗法。